| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hyperparathyroidism, Primary | 5 | 2023 | 33 | 1.490 |
Why?
|
| Postoperative Care | 4 | 2017 | 301 | 1.460 |
Why?
|
| Parathyroid Glands | 3 | 2023 | 28 | 1.430 |
Why?
|
| Thyroid Neoplasms | 7 | 2023 | 189 | 1.230 |
Why?
|
| Thyroidectomy | 6 | 2023 | 100 | 1.230 |
Why?
|
| Surgical Procedures, Operative | 2 | 2019 | 185 | 1.130 |
Why?
|
| Postoperative Period | 2 | 2019 | 334 | 1.130 |
Why?
|
| Ketamine | 7 | 2009 | 210 | 1.110 |
Why?
|
| Parathyroidectomy | 8 | 2023 | 49 | 1.110 |
Why?
|
| Time-to-Treatment | 2 | 2019 | 188 | 1.090 |
Why?
|
| Cholecystectomy | 2 | 2019 | 58 | 1.070 |
Why?
|
| Trauma Centers | 6 | 2022 | 183 | 1.050 |
Why?
|
| Postoperative Complications | 7 | 2019 | 3075 | 1.040 |
Why?
|
| Patient Participation | 2 | 2019 | 220 | 1.020 |
Why?
|
| Appendectomy | 2 | 2018 | 86 | 0.980 |
Why?
|
| Thyroid Gland | 2 | 2023 | 104 | 0.860 |
Why?
|
| Insurance Carriers | 1 | 2022 | 6 | 0.780 |
Why?
|
| Wounds, Penetrating | 4 | 2019 | 141 | 0.770 |
Why?
|
| Lipopolysaccharides | 12 | 2009 | 297 | 0.730 |
Why?
|
| Adrenal Insufficiency | 1 | 2021 | 28 | 0.720 |
Why?
|
| Cognitive Dysfunction | 1 | 2023 | 236 | 0.670 |
Why?
|
| Thyroid Nodule | 3 | 2019 | 19 | 0.660 |
Why?
|
| Medical Errors | 2 | 2019 | 155 | 0.650 |
Why?
|
| Cholecystitis, Acute | 1 | 2019 | 17 | 0.640 |
Why?
|
| Gastric Mucosa | 7 | 2008 | 488 | 0.620 |
Why?
|
| Resuscitation | 4 | 2016 | 249 | 0.590 |
Why?
|
| Patient Discharge Summaries | 1 | 2017 | 10 | 0.580 |
Why?
|
| Game Theory | 1 | 2017 | 3 | 0.570 |
Why?
|
| Safety-net Providers | 2 | 2017 | 52 | 0.560 |
Why?
|
| Comprehension | 1 | 2017 | 75 | 0.550 |
Why?
|
| Nitric Oxide Synthase | 6 | 2007 | 187 | 0.540 |
Why?
|
| Health Literacy | 1 | 2017 | 80 | 0.530 |
Why?
|
| Appendicitis | 1 | 2018 | 128 | 0.530 |
Why?
|
| Parathyroid Hormone | 2 | 2021 | 71 | 0.530 |
Why?
|
| Critical Illness | 1 | 2021 | 601 | 0.530 |
Why?
|
| Quality Improvement | 2 | 2019 | 645 | 0.520 |
Why?
|
| Delphi Technique | 1 | 2017 | 210 | 0.520 |
Why?
|
| Biopsy, Fine-Needle | 4 | 2023 | 117 | 0.510 |
Why?
|
| Male | 40 | 2023 | 61560 | 0.500 |
Why?
|
| Body Fluids | 2 | 2007 | 47 | 0.500 |
Why?
|
| Middle Aged | 25 | 2024 | 26943 | 0.500 |
Why?
|
| Health Care Surveys | 2 | 2015 | 285 | 0.500 |
Why?
|
| Female | 43 | 2024 | 66844 | 0.480 |
Why?
|
| Laparoscopy | 2 | 2018 | 493 | 0.480 |
Why?
|
| Nitric Oxide Synthase Type II | 9 | 2009 | 97 | 0.480 |
Why?
|
| Thoracotomy | 2 | 2016 | 111 | 0.480 |
Why?
|
| Models, Theoretical | 1 | 2017 | 364 | 0.480 |
Why?
|
| Child Care | 1 | 2015 | 11 | 0.480 |
Why?
|
| Transportation | 1 | 2015 | 26 | 0.470 |
Why?
|
| Patient Discharge | 3 | 2017 | 496 | 0.470 |
Why?
|
| Blood Loss, Surgical | 2 | 2015 | 153 | 0.470 |
Why?
|
| Patient Safety | 1 | 2019 | 401 | 0.460 |
Why?
|
| Humans | 60 | 2024 | 125269 | 0.460 |
Why?
|
| Patient Education as Topic | 1 | 2017 | 447 | 0.450 |
Why?
|
| Heme Oxygenase (Decyclizing) | 3 | 2009 | 12 | 0.450 |
Why?
|
| Vascular System Injuries | 1 | 2015 | 54 | 0.450 |
Why?
|
| Health Expenditures | 1 | 2015 | 103 | 0.440 |
Why?
|
| Arteries | 1 | 2015 | 225 | 0.440 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2007 | 293 | 0.430 |
Why?
|
| Adult | 24 | 2024 | 29652 | 0.420 |
Why?
|
| Liver Diseases | 2 | 2009 | 368 | 0.420 |
Why?
|
| Cost of Illness | 1 | 2015 | 252 | 0.420 |
Why?
|
| Patient Handoff | 1 | 2013 | 24 | 0.410 |
Why?
|
| Computers, Handheld | 2 | 2003 | 33 | 0.400 |
Why?
|
| Thrombelastography | 1 | 2013 | 57 | 0.390 |
Why?
|
| Rats, Sprague-Dawley | 12 | 2009 | 1243 | 0.390 |
Why?
|
| Hypothyroidism | 1 | 2013 | 91 | 0.390 |
Why?
|
| Anesthetics, Dissociative | 3 | 2007 | 18 | 0.380 |
Why?
|
| Blood Transfusion | 2 | 2013 | 313 | 0.370 |
Why?
|
| Poverty | 1 | 2015 | 425 | 0.370 |
Why?
|
| Monitoring, Intraoperative | 2 | 2020 | 133 | 0.370 |
Why?
|
| Texas | 6 | 2022 | 3588 | 0.360 |
Why?
|
| Endotoxemia | 3 | 2006 | 59 | 0.360 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 3 | 2023 | 50 | 0.350 |
Why?
|
| Emergencies | 1 | 2012 | 172 | 0.350 |
Why?
|
| General Surgery | 2 | 2014 | 206 | 0.340 |
Why?
|
| Healthcare Disparities | 1 | 2015 | 434 | 0.340 |
Why?
|
| Medical Audit | 1 | 2010 | 102 | 0.330 |
Why?
|
| Multiple Organ Failure | 2 | 2009 | 141 | 0.330 |
Why?
|
| Aged | 13 | 2023 | 19881 | 0.330 |
Why?
|
| Rats | 13 | 2009 | 3727 | 0.310 |
Why?
|
| Enzyme Inhibitors | 3 | 2009 | 582 | 0.310 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 2 | 2007 | 83 | 0.310 |
Why?
|
| Gastric Juice | 2 | 2005 | 15 | 0.310 |
Why?
|
| Perfusion Imaging | 2 | 2020 | 12 | 0.300 |
Why?
|
| Isoflurane | 2 | 2005 | 41 | 0.300 |
Why?
|
| Emergency Service, Hospital | 2 | 2015 | 1070 | 0.300 |
Why?
|
| Surgeons | 3 | 2017 | 257 | 0.300 |
Why?
|
| Mitogen-Activated Protein Kinase 14 | 1 | 2007 | 6 | 0.270 |
Why?
|
| Video Recording | 2 | 2020 | 183 | 0.270 |
Why?
|
| I-kappa B Kinase | 1 | 2007 | 61 | 0.270 |
Why?
|
| Endovascular Procedures | 1 | 2015 | 737 | 0.270 |
Why?
|
| NG-Nitroarginine Methyl Ester | 2 | 2006 | 59 | 0.260 |
Why?
|
| Mass Spectrometry | 3 | 2024 | 332 | 0.260 |
Why?
|
| Minimally Invasive Surgical Procedures | 4 | 2014 | 201 | 0.260 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2007 | 174 | 0.260 |
Why?
|
| Incidence | 6 | 2019 | 3148 | 0.260 |
Why?
|
| Adipocytes | 2 | 2018 | 141 | 0.250 |
Why?
|
| Gastrointestinal Tract | 1 | 2007 | 216 | 0.240 |
Why?
|
| Pancreatic Neoplasms | 2 | 2021 | 691 | 0.240 |
Why?
|
| Parathyroid Neoplasms | 2 | 2018 | 22 | 0.240 |
Why?
|
| Treatment Outcome | 11 | 2018 | 12392 | 0.240 |
Why?
|
| Margins of Excision | 2 | 2024 | 51 | 0.240 |
Why?
|
| Stomach Diseases | 1 | 2005 | 56 | 0.240 |
Why?
|
| Adenoma | 2 | 2018 | 129 | 0.230 |
Why?
|
| Injury Severity Score | 5 | 2019 | 226 | 0.230 |
Why?
|
| Liver | 3 | 2009 | 1748 | 0.230 |
Why?
|
| Anesthetics | 1 | 2005 | 79 | 0.220 |
Why?
|
| Prognosis | 5 | 2023 | 4646 | 0.220 |
Why?
|
| Hernia, Ventral | 2 | 2014 | 41 | 0.220 |
Why?
|
| Shock, Septic | 1 | 2005 | 147 | 0.220 |
Why?
|
| Suction | 1 | 2003 | 55 | 0.220 |
Why?
|
| Compartment Syndromes | 1 | 2003 | 31 | 0.210 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2018 | 472 | 0.210 |
Why?
|
| Herniorrhaphy | 2 | 2014 | 82 | 0.210 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2007 | 553 | 0.210 |
Why?
|
| Hospital Mortality | 4 | 2018 | 1026 | 0.210 |
Why?
|
| Education, Medical, Graduate | 1 | 2008 | 518 | 0.210 |
Why?
|
| Social Media | 2 | 2016 | 105 | 0.210 |
Why?
|
| Internship and Residency | 1 | 2013 | 1181 | 0.200 |
Why?
|
| Wound Healing | 2 | 2021 | 460 | 0.200 |
Why?
|
| Abdominal Injuries | 1 | 2003 | 112 | 0.200 |
Why?
|
| Oxidative Stress | 2 | 2023 | 837 | 0.200 |
Why?
|
| Acetylcysteine | 1 | 2023 | 72 | 0.200 |
Why?
|
| Biomedical Research | 1 | 2008 | 519 | 0.200 |
Why?
|
| Cyclooxygenase 2 | 3 | 2009 | 155 | 0.190 |
Why?
|
| Prospective Studies | 7 | 2019 | 6158 | 0.190 |
Why?
|
| Feasibility Studies | 2 | 2015 | 762 | 0.190 |
Why?
|
| Hemostasis, Surgical | 2 | 2011 | 37 | 0.180 |
Why?
|
| Clinical Protocols | 2 | 2013 | 240 | 0.180 |
Why?
|
| Retrospective Studies | 11 | 2021 | 16360 | 0.180 |
Why?
|
| Biomedical Technology | 1 | 2021 | 36 | 0.180 |
Why?
|
| Nerve Tissue Proteins | 1 | 2007 | 1113 | 0.180 |
Why?
|
| Hydrocortisone | 1 | 2021 | 218 | 0.170 |
Why?
|
| Sepsis | 1 | 2005 | 482 | 0.170 |
Why?
|
| Reference Standards | 1 | 2021 | 236 | 0.170 |
Why?
|
| Intraoperative Care | 2 | 2021 | 105 | 0.170 |
Why?
|
| Laparotomy | 2 | 2016 | 135 | 0.170 |
Why?
|
| Cicatrix | 1 | 2021 | 124 | 0.170 |
Why?
|
| Insulin-Secreting Cells | 1 | 2021 | 148 | 0.170 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2021 | 194 | 0.160 |
Why?
|
| Hospital Charges | 1 | 2019 | 60 | 0.160 |
Why?
|
| Oximetry | 2 | 2020 | 171 | 0.160 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2021 | 320 | 0.160 |
Why?
|
| Resilience, Psychological | 1 | 2019 | 69 | 0.150 |
Why?
|
| Breast Neoplasms | 2 | 2024 | 2513 | 0.150 |
Why?
|
| Self Efficacy | 1 | 2019 | 199 | 0.150 |
Why?
|
| Wounds and Injuries | 2 | 2012 | 370 | 0.150 |
Why?
|
| Health Resources | 1 | 2019 | 116 | 0.150 |
Why?
|
| Software | 1 | 2003 | 684 | 0.150 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2018 | 37 | 0.150 |
Why?
|
| Oxygen | 1 | 2021 | 557 | 0.140 |
Why?
|
| Insulin Resistance | 1 | 2023 | 641 | 0.140 |
Why?
|
| Animals | 15 | 2023 | 34238 | 0.140 |
Why?
|
| Hospitals, Private | 1 | 2017 | 18 | 0.140 |
Why?
|
| Cyclooxygenase Inhibitors | 3 | 2008 | 59 | 0.140 |
Why?
|
| Social Support | 1 | 2019 | 345 | 0.140 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2019 | 214 | 0.140 |
Why?
|
| Intensive Care Units | 1 | 2021 | 493 | 0.140 |
Why?
|
| Reading | 1 | 2017 | 79 | 0.140 |
Why?
|
| Cyclooxygenase 1 | 2 | 2008 | 42 | 0.140 |
Why?
|
| Morale | 1 | 2016 | 2 | 0.130 |
Why?
|
| Clothing | 1 | 2016 | 11 | 0.130 |
Why?
|
| Cardiolipins | 1 | 2016 | 18 | 0.130 |
Why?
|
| NF-kappa B | 3 | 2009 | 459 | 0.130 |
Why?
|
| Qualitative Research | 1 | 2019 | 547 | 0.130 |
Why?
|
| Gastrointestinal Transit | 2 | 2007 | 22 | 0.130 |
Why?
|
| Hospitals | 1 | 2019 | 398 | 0.130 |
Why?
|
| Laser-Doppler Flowmetry | 1 | 2016 | 66 | 0.130 |
Why?
|
| Mitochondria | 2 | 2023 | 680 | 0.130 |
Why?
|
| Continuity of Patient Care | 1 | 2017 | 154 | 0.130 |
Why?
|
| Operating Rooms | 1 | 2016 | 69 | 0.130 |
Why?
|
| Microcirculation | 1 | 2016 | 96 | 0.130 |
Why?
|
| Gastric Emptying | 2 | 2007 | 79 | 0.130 |
Why?
|
| Heme Oxygenase-1 | 2 | 2006 | 36 | 0.120 |
Why?
|
| Shock | 2 | 2009 | 90 | 0.120 |
Why?
|
| Critical Care | 1 | 2021 | 658 | 0.120 |
Why?
|
| Quality of Life | 2 | 2023 | 1939 | 0.120 |
Why?
|
| Young Adult | 6 | 2015 | 9056 | 0.120 |
Why?
|
| Up-Regulation | 2 | 2009 | 867 | 0.120 |
Why?
|
| Reperfusion Injury | 2 | 2006 | 115 | 0.120 |
Why?
|
| Anti-HIV Agents | 1 | 2018 | 320 | 0.120 |
Why?
|
| Lymph Nodes | 1 | 2017 | 379 | 0.120 |
Why?
|
| Internet | 2 | 2016 | 376 | 0.120 |
Why?
|
| Length of Stay | 2 | 2018 | 1312 | 0.120 |
Why?
|
| Electrocoagulation | 2 | 2011 | 36 | 0.110 |
Why?
|
| Hypoparathyroidism | 2 | 2011 | 10 | 0.110 |
Why?
|
| Multiple Trauma | 2 | 2012 | 64 | 0.110 |
Why?
|
| HIV-1 | 1 | 2018 | 465 | 0.110 |
Why?
|
| Hypotension | 1 | 2016 | 187 | 0.110 |
Why?
|
| Income | 1 | 2015 | 135 | 0.110 |
Why?
|
| Consensus | 1 | 2017 | 641 | 0.110 |
Why?
|
| Cell Phone | 1 | 2014 | 30 | 0.110 |
Why?
|
| Surgical Mesh | 1 | 2014 | 61 | 0.110 |
Why?
|
| Advanced Trauma Life Support Care | 1 | 2013 | 2 | 0.110 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2012 | 2107 | 0.110 |
Why?
|
| Physician-Patient Relations | 1 | 2017 | 429 | 0.110 |
Why?
|
| HIV | 1 | 2015 | 180 | 0.110 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2015 | 199 | 0.110 |
Why?
|
| Risk Factors | 3 | 2019 | 10319 | 0.110 |
Why?
|
| United States | 5 | 2018 | 10918 | 0.110 |
Why?
|
| Thyroiditis | 1 | 2013 | 2 | 0.110 |
Why?
|
| Adenoma, Oxyphilic | 1 | 2013 | 8 | 0.110 |
Why?
|
| Hospital Bed Capacity | 1 | 2013 | 25 | 0.110 |
Why?
|
| Communication | 1 | 2017 | 517 | 0.110 |
Why?
|
| Colostomy | 1 | 2013 | 26 | 0.110 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2021 | 817 | 0.100 |
Why?
|
| Databases, Factual | 1 | 2018 | 1180 | 0.100 |
Why?
|
| Ileostomy | 1 | 2013 | 31 | 0.100 |
Why?
|
| Abdominal Pain | 1 | 2015 | 309 | 0.100 |
Why?
|
| Stomach | 2 | 2005 | 270 | 0.100 |
Why?
|
| Thyroid Hormones | 1 | 2013 | 67 | 0.100 |
Why?
|
| Comorbidity | 1 | 2018 | 1535 | 0.100 |
Why?
|
| Task Performance and Analysis | 1 | 2013 | 93 | 0.100 |
Why?
|
| Platelet Transfusion | 1 | 2013 | 53 | 0.100 |
Why?
|
| Hemorrhage | 1 | 2016 | 470 | 0.100 |
Why?
|
| Natural Language Processing | 1 | 2013 | 63 | 0.100 |
Why?
|
| Wounds, Gunshot | 1 | 2013 | 139 | 0.100 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2013 | 79 | 0.100 |
Why?
|
| Focus Groups | 1 | 2013 | 200 | 0.100 |
Why?
|
| Gastrointestinal Diseases | 2 | 2007 | 339 | 0.100 |
Why?
|
| Bandages | 2 | 2021 | 56 | 0.100 |
Why?
|
| Abdominal Muscles | 1 | 2012 | 27 | 0.100 |
Why?
|
| Surgical Wound Infection | 1 | 2014 | 261 | 0.100 |
Why?
|
| Whole Body Imaging | 1 | 2012 | 29 | 0.100 |
Why?
|
| Workload | 1 | 2013 | 147 | 0.100 |
Why?
|
| Adipose Tissue | 1 | 2015 | 465 | 0.100 |
Why?
|
| Radiation Dosage | 1 | 2012 | 135 | 0.090 |
Why?
|
| Cholecystectomy, Laparoscopic | 1 | 2012 | 44 | 0.090 |
Why?
|
| Anesthesia, Local | 1 | 2012 | 47 | 0.090 |
Why?
|
| Erythrocyte Transfusion | 1 | 2013 | 130 | 0.090 |
Why?
|
| Diagnostic Errors | 1 | 2015 | 334 | 0.090 |
Why?
|
| Academic Medical Centers | 1 | 2013 | 308 | 0.090 |
Why?
|
| Reoperation | 2 | 2014 | 833 | 0.090 |
Why?
|
| Anesthetics, Local | 1 | 2012 | 83 | 0.090 |
Why?
|
| Ileum | 3 | 2006 | 132 | 0.090 |
Why?
|
| New South Wales | 1 | 2010 | 6 | 0.090 |
Why?
|
| Adrenocortical Carcinoma | 1 | 2010 | 9 | 0.090 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 2010 | 16 | 0.090 |
Why?
|
| Analysis of Variance | 3 | 2007 | 1020 | 0.090 |
Why?
|
| Pancreas | 2 | 2021 | 221 | 0.090 |
Why?
|
| Patient Readmission | 1 | 2013 | 385 | 0.080 |
Why?
|
| Adenocarcinoma, Follicular | 1 | 2009 | 11 | 0.080 |
Why?
|
| Incidental Findings | 1 | 2010 | 126 | 0.080 |
Why?
|
| Saline Solution, Hypertonic | 2 | 2006 | 19 | 0.080 |
Why?
|
| Metalloporphyrins | 1 | 2009 | 4 | 0.080 |
Why?
|
| Protoporphyrins | 1 | 2009 | 8 | 0.080 |
Why?
|
| Treatment Failure | 1 | 2010 | 341 | 0.080 |
Why?
|
| Carbon Monoxide | 1 | 2009 | 29 | 0.080 |
Why?
|
| Carcinoma, Papillary | 1 | 2009 | 71 | 0.080 |
Why?
|
| Neoplasm, Residual | 1 | 2009 | 122 | 0.080 |
Why?
|
| Pain, Postoperative | 1 | 2012 | 258 | 0.080 |
Why?
|
| PPAR gamma | 1 | 2009 | 88 | 0.080 |
Why?
|
| Alanine Transaminase | 1 | 2009 | 157 | 0.080 |
Why?
|
| Lymph Node Excision | 1 | 2009 | 166 | 0.080 |
Why?
|
| Financial Support | 1 | 2008 | 8 | 0.070 |
Why?
|
| Cells, Cultured | 3 | 2021 | 3056 | 0.070 |
Why?
|
| Lymphatic Metastasis | 1 | 2009 | 418 | 0.070 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2009 | 108 | 0.070 |
Why?
|
| Research Design | 1 | 2012 | 695 | 0.070 |
Why?
|
| Immunity, Mucosal | 1 | 2008 | 87 | 0.070 |
Why?
|
| Global Health | 1 | 2012 | 564 | 0.070 |
Why?
|
| Population Surveillance | 1 | 2009 | 389 | 0.070 |
Why?
|
| Career Choice | 1 | 2008 | 148 | 0.070 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2009 | 307 | 0.070 |
Why?
|
| Blotting, Western | 2 | 2006 | 1102 | 0.070 |
Why?
|
| Cross-Sectional Studies | 1 | 2015 | 3432 | 0.060 |
Why?
|
| Survival Rate | 3 | 2019 | 2062 | 0.060 |
Why?
|
| Splanchnic Circulation | 1 | 2006 | 53 | 0.060 |
Why?
|
| Aged, 80 and over | 2 | 2015 | 6603 | 0.060 |
Why?
|
| Coculture Techniques | 2 | 2018 | 227 | 0.060 |
Why?
|
| Calcium | 2 | 2010 | 1102 | 0.060 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2007 | 443 | 0.060 |
Why?
|
| Shock, Hemorrhagic | 1 | 2006 | 54 | 0.060 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2006 | 97 | 0.060 |
Why?
|
| Ileus | 1 | 2005 | 10 | 0.060 |
Why?
|
| Nitric Oxide Synthase Type I | 1 | 2005 | 31 | 0.060 |
Why?
|
| Fluid Therapy | 1 | 2006 | 129 | 0.060 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2005 | 57 | 0.060 |
Why?
|
| Anesthetics, Inhalation | 1 | 2005 | 45 | 0.060 |
Why?
|
| Gastroparesis | 1 | 2006 | 67 | 0.060 |
Why?
|
| Lysine | 1 | 2005 | 196 | 0.060 |
Why?
|
| Drug Interactions | 1 | 2005 | 257 | 0.060 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2005 | 219 | 0.060 |
Why?
|
| Gene Expression | 1 | 2009 | 1560 | 0.060 |
Why?
|
| Time Factors | 2 | 2005 | 6339 | 0.060 |
Why?
|
| Mastectomy | 1 | 2024 | 64 | 0.060 |
Why?
|
| Skin Care | 1 | 2003 | 14 | 0.050 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2017 | 584 | 0.050 |
Why?
|
| Intestinal Mucosa | 2 | 2006 | 778 | 0.050 |
Why?
|
| Fasciotomy | 1 | 2003 | 27 | 0.050 |
Why?
|
| Cutaneous Fistula | 1 | 2003 | 22 | 0.050 |
Why?
|
| Cytokines | 1 | 2009 | 1289 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2009 | 1140 | 0.050 |
Why?
|
| Decompression, Surgical | 1 | 2003 | 96 | 0.050 |
Why?
|
| Information Dissemination | 2 | 2016 | 186 | 0.050 |
Why?
|
| Breast | 1 | 2024 | 213 | 0.050 |
Why?
|
| Escherichia coli | 1 | 2008 | 985 | 0.050 |
Why?
|
| Suture Techniques | 1 | 2003 | 195 | 0.050 |
Why?
|
| Glycine | 1 | 2023 | 168 | 0.050 |
Why?
|
| Re-Epithelialization | 1 | 2021 | 11 | 0.050 |
Why?
|
| Common Bile Duct | 1 | 2021 | 14 | 0.050 |
Why?
|
| Glutathione | 1 | 2023 | 196 | 0.050 |
Why?
|
| Statistics as Topic | 1 | 2021 | 256 | 0.040 |
Why?
|
| Motion | 1 | 2020 | 43 | 0.040 |
Why?
|
| Algorithms | 2 | 2020 | 1630 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2003 | 1506 | 0.040 |
Why?
|
| Lipids | 1 | 2023 | 523 | 0.040 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2021 | 154 | 0.040 |
Why?
|
| Health Promotion | 1 | 2023 | 389 | 0.040 |
Why?
|
| DNA Mutational Analysis | 1 | 2021 | 794 | 0.040 |
Why?
|
| Artifacts | 1 | 2020 | 109 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 2 | 2012 | 511 | 0.040 |
Why?
|
| Dietary Supplements | 1 | 2023 | 472 | 0.040 |
Why?
|
| Recurrence | 2 | 2014 | 1420 | 0.040 |
Why?
|
| Image Enhancement | 1 | 2020 | 163 | 0.040 |
Why?
|
| Syndrome | 1 | 2021 | 1121 | 0.040 |
Why?
|
| Neoplasms | 1 | 2013 | 2790 | 0.040 |
Why?
|
| Four-Dimensional Computed Tomography | 1 | 2018 | 5 | 0.040 |
Why?
|
| Single Photon Emission Computed Tomography Computed Tomography | 1 | 2018 | 7 | 0.040 |
Why?
|
| Technetium Tc 99m Sestamibi | 1 | 2018 | 25 | 0.040 |
Why?
|
| Tenofovir | 1 | 2018 | 18 | 0.040 |
Why?
|
| Disease Reservoirs | 1 | 2018 | 35 | 0.040 |
Why?
|
| Homeodomain Proteins | 1 | 2021 | 548 | 0.040 |
Why?
|
| Choristoma | 1 | 2018 | 50 | 0.040 |
Why?
|
| Prodrugs | 1 | 2018 | 59 | 0.040 |
Why?
|
| Trans-Activators | 1 | 2021 | 798 | 0.030 |
Why?
|
| Glycerophospholipids | 1 | 2017 | 7 | 0.030 |
Why?
|
| Glycolipids | 1 | 2017 | 32 | 0.030 |
Why?
|
| Sphingolipids | 1 | 2017 | 28 | 0.030 |
Why?
|
| Hyperemia | 1 | 2016 | 27 | 0.030 |
Why?
|
| Signal-To-Noise Ratio | 1 | 2016 | 41 | 0.030 |
Why?
|
| Likelihood Functions | 1 | 2016 | 114 | 0.030 |
Why?
|
| Aging | 1 | 2023 | 1181 | 0.030 |
Why?
|
| Gallbladder Diseases | 1 | 2015 | 24 | 0.030 |
Why?
|
| Hand | 1 | 2016 | 100 | 0.030 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2016 | 128 | 0.030 |
Why?
|
| Inflammation | 1 | 2023 | 1446 | 0.030 |
Why?
|
| Hospitals, Urban | 1 | 2015 | 97 | 0.030 |
Why?
|
| Perfusion | 1 | 2016 | 207 | 0.030 |
Why?
|
| Guidelines as Topic | 1 | 2016 | 196 | 0.030 |
Why?
|
| Medical History Taking | 1 | 2015 | 108 | 0.030 |
Why?
|
| Child | 1 | 2015 | 24431 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2014 | 5180 | 0.030 |
Why?
|
| Fatty Acids | 1 | 2017 | 344 | 0.030 |
Why?
|
| Virus Replication | 1 | 2018 | 607 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2007 | 4534 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2021 | 1898 | 0.030 |
Why?
|
| DNA, Viral | 1 | 2015 | 480 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2006 | 1290 | 0.030 |
Why?
|
| Skin | 1 | 2016 | 519 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2013 | 286 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 824 | 0.030 |
Why?
|
| Biomarkers | 2 | 2016 | 3091 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 2015 | 701 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2015 | 797 | 0.030 |
Why?
|
| Gene Expression Regulation | 1 | 2021 | 2522 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2016 | 697 | 0.020 |
Why?
|
| Surgical Instruments | 1 | 2012 | 56 | 0.020 |
Why?
|
| Glasgow Coma Scale | 1 | 2012 | 205 | 0.020 |
Why?
|
| Terminology as Topic | 1 | 2013 | 223 | 0.020 |
Why?
|
| Recurrent Laryngeal Nerve Injuries | 1 | 2011 | 16 | 0.020 |
Why?
|
| Urinary Tract Infections | 1 | 2015 | 298 | 0.020 |
Why?
|
| Australia | 1 | 2011 | 137 | 0.020 |
Why?
|
| Hospitalization | 1 | 2019 | 1789 | 0.020 |
Why?
|
| Nerve Block | 1 | 2012 | 65 | 0.020 |
Why?
|
| Postoperative Hemorrhage | 1 | 2011 | 84 | 0.020 |
Why?
|
| Adrenalectomy | 1 | 2010 | 38 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2012 | 345 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2013 | 1259 | 0.020 |
Why?
|
| Adolescent | 3 | 2016 | 19362 | 0.020 |
Why?
|
| Logistic Models | 1 | 2014 | 1812 | 0.020 |
Why?
|
| Immunoassay | 1 | 2009 | 130 | 0.020 |
Why?
|
| Risk | 1 | 2010 | 756 | 0.020 |
Why?
|
| Nitrobenzenes | 1 | 2008 | 19 | 0.020 |
Why?
|
| Salicylates | 1 | 2008 | 54 | 0.020 |
Why?
|
| Bayes Theorem | 1 | 2009 | 284 | 0.020 |
Why?
|
| Indomethacin | 1 | 2008 | 84 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2010 | 1056 | 0.020 |
Why?
|
| Gelatinases | 1 | 2006 | 15 | 0.020 |
Why?
|
| Isotonic Solutions | 1 | 2006 | 35 | 0.020 |
Why?
|
| Transcription Factor AP-1 | 1 | 2006 | 109 | 0.020 |
Why?
|
| HIV Infections | 1 | 2018 | 1899 | 0.020 |
Why?
|
| Mice | 1 | 2023 | 17635 | 0.020 |
Why?
|
| Sulfonamides | 1 | 2008 | 271 | 0.020 |
Why?
|
| Imines | 1 | 2005 | 9 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2009 | 1275 | 0.020 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2005 | 126 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2005 | 132 | 0.020 |
Why?
|
| Probability | 1 | 2006 | 320 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2006 | 230 | 0.020 |
Why?
|
| Pyrazoles | 1 | 2008 | 305 | 0.020 |
Why?
|
| Disease Models, Animal | 2 | 2006 | 4396 | 0.010 |
Why?
|
| Ethanol | 1 | 2006 | 163 | 0.010 |
Why?
|
| Random Allocation | 1 | 2006 | 441 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2009 | 1396 | 0.010 |
Why?
|
| Caspases | 1 | 2005 | 162 | 0.010 |
Why?
|
| Extracellular Matrix | 1 | 2006 | 238 | 0.010 |
Why?
|
| Reference Values | 1 | 2006 | 718 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2009 | 2174 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2010 | 3304 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2006 | 1697 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2006 | 1693 | 0.010 |
Why?
|
| Base Sequence | 1 | 2006 | 3103 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2006 | 2058 | 0.010 |
Why?
|
| Models, Biological | 1 | 2006 | 1460 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2006 | 3892 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2006 | 2820 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2009 | 3465 | 0.010 |
Why?
|
| Apoptosis | 1 | 2005 | 1806 | 0.010 |
Why?
|
| Lung | 1 | 2006 | 1496 | 0.010 |
Why?
|